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Background: Recent studies suggest that epigenetic factors may play an important role in the pathogenesis of
Parkinson’s disease (PD). In our previous work, we sequenced the exomes of sixteen patients from eight Chinese PD
families using whole exome sequencing technology, consequently three patients from different pedigrees were found
sharing the variant c.1460C > T (rs150689919) in the coding region of the Tet methyl cytosine dioxygenase 1 (TET1) gene.
Methods: In order to evaluate the possible association between sporadic PD and the single nucleotide polymorphism
(SNP) rs150689919 in TET1, a case–control cohort study was conducted in 514 sporadic PD patients and 529 normal
controls. Genotyping was determined by PCR and direct sequencing. Statistical significance was analyzed by the
Chi-squared test.
Results: There was no statistical significance in TET1 rs150689919 genotype or allele frequencies between the PD cases
and healthy controls, even after being stratified by gender and age at onset.
Conclusions: Our findings suggest that rs150689919 in TET1 may not be associated with PD in Chinese population.
However, due to the limited data in this study, replication studies in larger sample and other populations are required.
Keywords: TET1, Parkinson’s disease, Epigenetics, ChineseBackground
Parkinson’s disease (PD) is the second most common
progressive neurodegenerative disorder worldwide after
only Alzheimer’s disease. Resting tremors, muscular rigidity,
bradykinesia, postural instability, and positive response
to dopamine replacement therapy are the main clinical
manifestations of the condition [1]. Familial forms repre-
sent only a minority of the cases (ranging from 5 to 10%
of the total), whereas the vast majority of PD occurs as
sporadic forms [2]. Although the etiology of idiopathic
PD remains unclear, there is a growing body of evidence
suggesting that a large proportion of these cases are also
significantly influenced by genetic factors. Genetic associ-
ation studies based on the “candidate gene approach” and* Correspondence: shenlu2505@126.com
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reproduction in any medium, provided the orgenome-wide association studies have revealed several
genetic variants that might act as susceptibility factors
for the sporadic cases [http://www.pdgene.org/] [3].
Recently, exome sequencing has emerged as a feasible,
cost-effective, and high-throughput strategy that enables
the detection of rare coding variants, offering new insight
to investigate the association between rare variants and
complex diseases. In our previous work, whole exome
capture and high-throughput sequencing technology were
carried out in 16 patients from eight pedigrees clinically
diagnosed as PD to identify the potential causative genes
(data not shown). Many studies have shown that some
causative genes for Mendelian-inherited PD, such as
SNCA and PARK16, were also identified and confirmed as
susceptibility genes for sporadic PD [http://www.pdgene.
org/] [3]. Therefore, we performed a comparison of the
exome data to screen for some potential susceptibility
variants for idiopathic PD. Because rare variants might
have more marked functional consequences, we first. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eight previous exome-sequenced HapMap samples (Hap-
Map 8), and the single nucleotide polymorphism (SNP)
release of the 1000 Genome Project (20100208 release).
The shared SNPs that had the population minor allele
frequencies (MAFs) more than 5% were removed. Subse-
quently, prediction tools SIFT [http://sift.jcvi.org/] and
PolyPhen-2 [http://genetics.bwh.harvard.edu/pph2/index.
shtml] were used to assess the non-synonymous variants
and identify those likely to have a functional impact [4].
The variants that affected the highly conserved sequences
or that were predicted to be deleterious were selected. As a
result, 28 variants from 25 genes had higher frequencies in
sixteen patients were found (see Additional file 1: Table S1).
In order to identify the most promising candidate variant,
the functional analysis of the 25 genes were conducted,
and the DNA demethylation gene, TET1, encodes the
human ten-eleven translocation 1 protein, was brought
to attention. Firstly, the variant rs150689919 in TET1 had
the highest frequency in the sixteen patients (three patients
from different families shared this variant, see Additional
file 2: Figure S1). Secondly, TET1 protein can convert
5-methylcytosine (5mC) into 5-hydroxymethylcytosine
(5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine
(5caC) through three consecutive oxidation reactions [5,6],
and these modified bases may represent new epigenetic
states in genomic DNA or intermediate in the process
of DNA demethylation [7,8]. As we know, substantial
evidences already revealed that methylation dysfunction
and expression changes were existed in PD and some PD
risk variants in SNCA, PARK16, GPNMB and STX1B
[9,10]. Considering the dysfunction of epigenetic machin-
ery may play an important role in the pathogenesis of PD
[10,11], and the relatively high frequency in our familial
PD cases, we chose rs150689919 in TET1 as the candidate
variant to perform a case–control cohort study to further




A total of 514 ethnic Han Chinese PD patients (267 males,
247 females) from the Department of Neurology, Xiangya
Hospital and the Key Laboratory of Neurodegenerative
Disorders in Hunan Province were enrolled in this study.Table 1 Genotype and allele frequencies of SNP rs150689919
SNP N Genotype N (%) p (d
CC CT TT
Patients 514 474 (92.2) 38 (7.4) 2 (0.4) 0.137a (d
Controls 529 477 (90.2) 52 (9.8) 0
p-Values after correcting by binary logistic regression with age and gender using SP
ap = 0.363; bp = 0.362.
*With df = 2, the OR value could not been given by Chi-square test.The patients had a mean age at onset of 54.82 ± 12.19 years
(range: 11-91 years). Early onset Parkinson’s disease
(EOPD) was defined as PD with an age at onset less
than 50 years (166 subjects), with the mean age at
onset of 40.89 ± 8.46 years (range: 11-50 years). Late
Onset Parkinson’s disease (LOPD) was defined as PD
with an age at onset more than 50 years (348 subjects),
with the mean age at onset of 61.47 ± 6.97 years (range:
51-91 years). All of the subjects were evaluated by two
experienced neurologists and diagnosed as idiopathic
PD based on the United Kingdom Parkinson’s Disease
Society Brain Bank Clinical Diagnostic Criteria [12]. None
of the patients had a reported family history of PD in one
or more first-or second-degree relatives. In addition, 529
unrelated individuals without symptoms of Parkinsonism,
Alzheimer’s disease, other extrapyramidal diseases as well
as family history of parkinsonism were enrolled in the
study and matched for age, gender, ethnicity, and area
of residence (261 males and 268 females; mean age
53.55 ± 6.26 years; range 15-90 years). The study was
approved by the Ethics Committee of Xiangya Hospital,
Central South University. A written informed consent was
obtained from each subject involved in the research.Polymorphism analysis
Blood samples were collected from all subjects using
ethylenediaminetetraacetic acid (EDTA) tubes. Genomic
DNA was extracted from peripheral blood leukocytes using
the standard phenol-chloroform extraction method. The
genotype was detected by direct sequencing using an ABI
3100 automated sequencer (Applied Bio systems, Foster
City, CA). A 637-bp fragment containing the variant was
amplified using the following primers: forward 5′-AGTT
TCTGATACCACCTCTTTCC-3′, and reverse 5′-GACCA
TTGGCACTGGCATAG-3′. Polymerase chain reaction
(PCR) was performed using the following amplification
conditions: 32 cycles of denaturation at 94°C for 45 s,
annealing at 64.6°C for 45 s, and extension at 72°C for
45 s. A final extension was performed for 10 min at 72°C.Statistical analysis
The Chi-squared test was used to test for allele and
genotype frequencies of the PD patients and controls.
A p-value < 0.05 using a two-tailed test was consideredin PD patients and controls
f, OR) Allele N (%) p (df, OR)
C T
f = 2, OR*) 986 (95.9) 42 (4.1) 0.361b (df = 1,OR = 0.824)
1006 (95.1) 52 (4.9)
SS17.0.
Table 2 Genotype and allele frequencies of rs150689919 in male/female PD patients and controls
SNP N Genotype N (%) p (df, OR) Allele N (%) p (df, OR)
CC CT TT C T
Male 267 248 (92.9) 18 (6.7) 1 (0.4) 0.208a (df = 2, OR*) 514 (96.3) 20 (3.7) 0.261b (df = 1, OR = 0.713)
Controls 261 234 (89.7) 27 (10.3) 0 495 (94.8) 27 (5.2)
Female 247 226 (91.5) 20 (8.1) 1 (0.4) 0.517c (df = 2, OR*) 472 (95.5) 22 (4.5) 0.871d (df = 1, OR = 0.953)
Controls 268 243 (90.7) 25 (9.3) 0 511 (95.3) 25 (4.7)
p-Values after correcting by binary logistic regression with age using SPSS17.0.
ap = 0.267; bp = 0.266; cp = 0.881; dp = 0.881.
*With df = 2, the OR value could not been given by Chi-square test.
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using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA).
Results
Genotype and allele frequencies for all 1058 subjects
(514 patients and 529 healthy controls) were shown in
Table 1. The SNP was in agreement with Hardy-Weinberg
equilibrium in both groups. There was no significant
difference in genotype and allele frequencies between
cases and controls (p = 0.137 for genotype frequency;
p = 0.361 for allele frequency). Genotype and allele fre-
quencies of rs150689919 in patients and controls of
both genders were shown in Table 2. No statistically
significant difference was found in either genotype or
allele frequencies between male or female cases and con-
trols (male, p = 0.208 and p = 0.261, respectively; female,
p = 0.517 and p = 0.871, respectively). The genotype and
allele frequencies of rs150689919 in EOPD and LOPD
cases were shown in Table 3. There was no significant
difference observed in either allele or genotype distribution
in EOPD or LOPD cases compared to controls (EOPD,
p = 0.296 and p = 0.176, respectively; LOPD, p = 0.671 and
p = 0.176, respectively).
Discussion
In current study, we investigated the association of SNP
rs150689919 and risk of PD for the first time in a cohort
of Chinese subjects with PD and normal controls. However,
we did not find a statistically significant difference between
PD patients and controls in either allele or genotypeTable 3 Genotype and allele frequencies of rs150689919 in E
SNP N Genotype N (%) p (d
CC CT TT
EOPD 166 156 (94.0) 9 (5.4) 1 (0.6) 0.176a (d
Controls 195 176 (92.3) 19 (9.7) 0
LOPD 348 318 (91.4) 29 (8.3) 1 (0.3) 0.487c (d
Controls 334 301 (90.1) 33 (9.9) 0
p-Values after correcting by binary logistic regression with age and gender using SP
ap = 0.423; bp = 0.432; cp = 0.665; dp = 0.668.
EOPD, early onset Parkinson’s disease (age at onset ≤ 50); LOPD, late onset Parkinso
*With df = 2, the OR value could not been given by Chi-square test.distribution, even after stratification by gender and age
at onset. Therefore, the data obtained to date do not
support an association between SNP rs150689919 and
sporadic PD in Chinese population.
Rare variants, which have minor allele frequencies
(MAFs) <1%, might exert large effect sizes on the complex
diseases. The glucocerebrosidase gene (GBA) serves as an
example in PD: carriers of mutations in GBA causing
Gaucher’s disease are at significantly increased risk for
developing PD, with an earlier age of onset compared
with PD patients who do not carry these mutations [11-13].
The identification of such variants will allow for a more
complete understanding of the etiology of PD. Exome
sequencing, which can screen the variants located in exons
precisely and efficiently, could be used in complementation
with GWAS to study the genetic basis of complex diseases.
Herein, we attempted a new approach to detect suscepti-
bility factors for sporadic PD. The DNA sequence variant
rs150689919 was extracted from the whole exome
sequencing results of a group of familial patients with PD
and based on its potential involvement in the pathogenesis
of PD. Through the combination of exome sequencing
and the classical “candidate gene approach”, we can not
only extended genetics studies of PD to include rare coding
variants but also overcome the limitation of sample size
and expensive costs associated with case–control allelic
association studies built on whole-exomes.
There are several possible reasons for the negative results
obtained in this study. First, the ethnic or geographic origin
of subjects may account for the specific SNP frequenciesOPD/LOPD patients and controls
f, OR) Allele N (%) p (df, OR)
C T
f = 2, OR*) 321 (96.7) 11 (3.3) 0.296b (df = 1, OR = 0.669)
371 (95.1) 19 (4.9)
f = 2, OR*) 665 (95.5) 31 (4.5) 0.671d (df = 1, OR = 0.897)
635 (95.6) 33 (4.7)
SS17.0.
n’s disease (age at onset > 50).
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from the 1000 Genomes project originated from the
genomes of approximately 2500 unidentified people
from ~25 populations around the world, while the sub-
jects recruited in this study originated mainly from the
mid-south of China. This might explain the difference
in SNP frequencies between our controls and the 1000
Genomes project (allele T = 4.9% vs. 1.1%, respectively).
Thus, the SNP with evidence suggesting an association
with PD should be investigated in other independent
samples. Second, when selecting candidate variants of
complex disorders from exome sequences, it requires
moderate sample size, or informative pedigrees to simplify
the filtering of variants [15]. In this study, due to the
limited sample size of the PD pedigrees and the rare
frequencies of the risk alleles in the population, we failed
to identify the risk variant for PD. Therefore, when we
conduct exome-sequencing studies, various factors should
be taken into consideration, such as the characteristics
of the study population, genetic heterogeneity of the
phenotype, and the sample size.
Although positive results were not obtained in our
study, the combination of exome sequencing and the
classical “candidate gene approach” is still useful for
identifying susceptibility genes. In addition, larger sample
studies should be conducted to further evaluate the poten-
tial association between SNP rs150689919 and PD or other
neurodegenerative disorders in samples with different
ethnic or geographic origins.
Conclusion
To our knowledge, this is the first study to assess the
frequency of rs150689919 in a cohort of Chinese PD
patients and controls. Our results suggest that rs150689919
in TET1 may not be associated with PD in ethnic Han
Chinese population. However, due to the limited data in
the present study, replication studies in larger sample and
other populations are required.
Additional files
Additional file 1: Table S1. Candidate variants from exome sequencing
of eight PD families.
Additional file 2: Figure S1. Pedigrees with variant TET1 rs150689919.
Each proband was indicated by an arrow. Patient II:2 in Family M17306,
patient II:2 in Family M8302 and patient II:3 in Family M13742 shared the
variant TET1 rs1506899.
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